Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. | Profiles RNS

RCMI Coordinating Center (RCMI CC)

Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies.

Fryar-Tita EB, Das JR, Davis JH, Desoto JA, Green S, Southerland WM, Bowen D. Raloxifene and selective cell cycle specific agents: a case for the inclusion of raloxifene in current breast cancer treatment therapies. Anticancer Res. 2007 May-Jun; 27(3B):1393-9.

View in: PubMed

authors with profiles

William M. Southerland

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support